Table 4.
Seroconversion Rates Post Initial Vaccination According to Type of Targeted Therapy Received
| Author | CLL N | Response (n Evaluable) | ||||
|---|---|---|---|---|---|---|
| Targeted Treatment | Venetoclax Mono | BCL2i ± Combo | BTKi | Anti-CD20 Response ± Targeted | ||
| Second dose | ||||||
| Sun et al (2021)35 | 58 | NA | 100% (1) | NA | 55% (29) | 20% (5) |
| Molica et al (2021)33 | 70 | 43% (35) | NA | NA | NA | 10% (10) |
| Parry et al (2022)36 | 500 | 24% (114) | 38% (16) | 0% (5)a | 34% (93)b | NA |
| Bagacean et al (2022)32 | 506 | NA | 52% (23) | 0% (6)a | 22% (104) | 0% (19) |
| Bergman et al (2021)34 | 79 | NA | NA | NA | 26.9% (26) | NA |
| Molica et al (2022)31 | 2082 | NA | NA | 32% (94) | 29% (325) | 41% (254) |
| Benjamini et al (2022)37 | 373 | 14% (113) | 62% (13) | 6% (34) | 18% (79) | 14% (49) |
| Roeker et al (2021)38 | 44 | NA | NA | NA | 21% (14) | 10% (21) |
| Tadmor et al (2021)39 | 84 | NA | NA | 16.7% (6) | 36.4% (4) | NA |
| Herishanu et al (2021)40 | 167 | NA | 40% (5) | 13.6% (22) | 16% (50) | NA |
| Greenberger et al (2021)28 | 650 | NA | NA | 39.3% (28) | 47.5% (282) | 36.9% (263) |
| Shen et al (2022)27 | 160 | 16% (25) | NAc | NA | 14.3% (21) | NA |
| Ujjani et al (2022)23 | 37 | NA | NA | NA | 33% (15) | 38% (8)d |
| Haydu et al (2022)41 | 36 | NA | NA | NA | 33% (6) | NA |
| Haggenburg (2022)45 | 94 | NA | NA | NA | 27% (34) | NA |
| Third dosee | ||||||
| Herishanu et al (2022)42 | 172 | NA | 60% (5) | NA | 15.3% (59) | 7.7% (39) |
| Del Poeta et al (2021)44 | 46 | NA | 25% (8) | NA | 38.1% (21) | NA |
aPatients receiving venetoclax + a BTKi.
bBTKi monotherapy.
cFour patients (response 25%) were on venetoclax, but had completed anti-CD20 therapy within the last 12 mo.
dVenetoclax + anti-CD20 therapy ongoing/within 1 y.
eHerishanu: seronegative after initial vaccination; Del Poeta: any patient (may include prior treatment).
BCL2i = B-cell lymphoma-2 inhibitor; BTKi = Bruton tyrosine kinase inhibitor; CLL = chronic lymphocytic leukemia; Combo = combination therapy; Mono = monotherapy; n = number of patients; NA = not available.